Gruppo Oncologico Del Nord-ovest

This phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has …

This trial tests a new way of taking the drug sonidegib for people with advanced basal cell carcinoma that cannot be surgically removed. Instead of taking the drug continuously, patients who have already achieved a complete response will take it in cycles with breaks (14 days on/…

This study is testing whether a combination of three drugs—trifluridine/tipiracil, capecitabine, and bevacizumab—can safely control metastatic colorectal cancer in people who are not healthy enough for standard intensive chemotherapy. The first part finds the best dose, and the s…

This phase 2 trial is testing two different sequences of the drugs panitumumab and regorafenib in 214 patients with advanced colorectal cancer that no longer responds to standard treatments. The goal is to see which order of these drugs helps patients live longer. Participants mu…

This study tests whether using a blood test for circulating tumor DNA (ctDNA) can help doctors decide if patients with stage II or III colon cancer need stronger chemotherapy after surgery. The trial compares standard chemo with a more intense regimen (FOLFOXIRI) and an additiona…

This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…

This study is for people with a certain genetic type of advanced colorectal cancer (BRAF V600E) who previously benefited from a specific drug combination (encorafenib plus cetuximab). Researchers want to see if giving these drugs again, guided by a blood test that looks for cance…